GCM
CSTL icon

Graham Capital Management’s Castle Biosciences CSTL Stock Holding History

Graham Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,133
Closed -$273K – 1306
2026
Q1 		$273K Buy
11,133
+205
+2% +$6.71K 0.01% 852
2025
Q4 		$425K Sell
10,928
-10,205
-48% -$329K 0.01% 694
2025
Q3 		$481K Sell
21,133
-20,650
-49% -$419K 0.01% 628
2025
Q2 		$853K Sell
41,783
-26,602
-39% -$492K 0.01% 632
2025
Q1 		$1.37M Buy
68,385
+26,709
+64% +$661K 0.02% 454
2024
Q4 		$1.11M Buy
41,676
+26,000
+166% +$792K 0.02% 466
2024
Q3 		$447K Buy
15,676
+824
+6% +$21K 0.01% 666
2024
Q2 		$323K Buy
14,852
+2,662
+22% +$59.3K 0.01% 706
2024
Q1 		$270K Sell
12,190
-2,690
-18% -$58.5K 0.01% 823
2023
Q4 		$321K Buy
+14,880
New +$262K 0.01% 708
2023
Q2 		– Sell
-31,011
Closed -$705K – 1015
2023
Q1 		$705K Buy
31,011
+4,076
+15% +$99.6K 0.02% 635
2022
Q4 		$634K Sell
26,935
-17,862
-40% -$414K 0.02% 689
2022
Q3 		$1.17M Sell
44,797
-28,875
-39% -$809K 0.05% 420
2022
Q2 		$1.62M Buy
+73,672
New +$1.71M 0.07% 279

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Graham Capital Management's CSTL Position: Q2 2026 in Review

Graham Capital Management sold out of Castle Biosciences (CSTL) in Q2 2026, closing a stake of 11,133 shares — an estimated $273K sold.

Graham Capital Management first reported a position in CSTL in Q2 2022 and held it in 14 quarters. The position peaked at $1.62M in Q2 2022. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Graham Capital Management reported no remaining Castle Biosciences position as of Q2 2026 after selling out during the quarter.
  • Graham Capital Management sold 11,133 Castle Biosciences shares in Q2 2026, an estimated $273K.
  • Graham Capital Management first reported a position in Castle Biosciences in Q2 2022 and held it in 14 quarters.
  • Graham Capital Management's Castle Biosciences position peaked at $1.62M in Q2 2022.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.